The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2019, 2020 and 2025 (forecasted). This report reviews liquid biopsy biomarkers and technologies and provides background on why liquid biopsy is increasingly viewed as a replacement for, or a companion to, tissue biopsy. The report then discusses several of the significant large-scale research initiatives that are contributing to liquid biopsy development. The key forces driving the market are enumerated.
The structures of several important industry subsectors, as well as major industry acquisitions and strategic alliances from January 2019 through January 2021, are reviewed. The industry subsectors that have been analyzed include DNA sequencing and instruments; long-read sequencing; sequencing informatics; PCR; droplet digital PCR; CTC capture and detection; liquid biopsy; cancer screening/early detection; and noninvasive prenatal screening.
The market for liquid biopsy diagnostics is analyzed in depth. The market is analyzed by:
- Application (cancer, reproductive health, transplant)
- Biomarker type, including circulating nucleic acids, circulating tumor cells, and other (extracellular vesicles, proteins)
- Analysis platforms including NGS, PCR and other (microarray, Sanger sequencing, immunoassay, immunocytochemistry, and cell capture)
- Analysis purpose (screening/early detection, diagnosis, therapy guidance, monitoring)
- Geography (North America, Europe, Asia-Pacific, Rest of World)
- Market data covers 2019, 2020 and 2025 (forecasted)
The report contains a large profile compilation of more than 200 companies in the liquid biopsy industry.
The report provides a summary of the main industry acquisitions and strategic alliances from January 2019 through January 2021, including key alliance trends.
The report includes:
- 29 data tables and 56 additional tables
- An overview of the global market for liquid biopsy research tools, services and diagnostics
- Estimation of the market size and analyses of global market trends, with data from 2019 and 2020, and projections of compound annual growth rates (CAGRs) through 2025
- Characterization and quantification of market potential for liquid biopsy diagnostics by application, biomarker type, analysis platform, analysis purpose and geographical region
- Discussion on significant large-scale research initiatives that are contributing to liquid biopsy market development
- Examination of various conventional biopsy methods and information on how liquid biopsy enabling technologies to address the issues and are gaining significant traction with key opinion leaders
- Identification of market drivers, restraints and other forces influencing the growth of the liquid biopsy market
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Review of patents and new developments in circulating tumor cell (CTC) technologies, exosome technologies, cell-free DNA technologies, and cancer biomarkers
- Company profiles of major liquid biopsy market players, including Bard1 Life Sciences Ltd., Becton, Dickinson and Co. (BD), Bio-Rad Laboratories Inc., Danaher Corp., Exosome Sciences Inc., Qiagen NV and Roche Holding AG
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview
- Introduction
- Scope of Report
- Liquid Biopsy vs. Traditional Biopsy
- Markets
- Forces Driving Growth
- Key Trends
- Industry
Chapter 4 Technology Background
- Liquid Biopsy Biomarkers
- Cancer Genomics
- Noninvasive Prenatal Testing (NIPT)
- Circulating Tumor Cell Technologies (CTCs)
- CTC Workflow
- Cell Isolation Technologies
- CTC Sample Preparation Technologies
- CTC Downstream Analysis Technologies
- Comparison of Liquid Biopsy with Conventional Biopsy
- Cancer Testing
- Prenatal Testing
Chapter 5 Liquid Biopsy Initiatives
- Introduction
- Liquid Biopsy-Related Research and Development
- Initiatives and Programs
- Population Sequencing Projects
Chapter 6 Liquid Biopsy Applications
- Introduction
- Cancer Applications
- Precision Medicine
- Liquid Biopsy Biomarkers
- Cancer Market Segments
- Reproductive Health Applications
- Transplant Diagnostic Applications
Chapter 7 Liquid Biopsy Industry
- Introduction
- Sequencing Instruments Industry
- Third-Generation Sequencing Industry
- Sequencing Informatics Industry
- PCR Industry
- Droplet Digital PCR Industry
- CTC Capture and Detection Industry
- Liquid Biopsy Assay Industry
- Liquid Biopsy Cancer Screening/Early Detection Industry
- Noninvasive Prenatal Testing (NIPT) Industry
Chapter 8 Industry Acquisitions and Strategic Alliances
- Acquisitions
- Strategic Alliances
- Key Trends
- Summary of Alliances
Chapter 9 Markets for Liquid Biopsy
- Forces Driving Growth in the Markets for Liquid Biopsy
- Precision Medicine
- Rise of Tissue-Agnostic Drugs
- Genomics Initiatives
- Clinical Need for Better Diagnostics
- Role of Key Stakeholders
- Emerging "Mega" Applications
- COVID-19 Environment
- Rise in the Importance of China
- Impact of COVID-19 on the Global Market for Liquid Biopsy
- Global Market for Liquid Biopsy by Clinical Category
- Global Market for Liquid Biopsy by Purpose of Analysis
- Global Market for Liquid Biopsy by Biomarker Type
- Global Market for Liquid Biopsy by Analysis Platform
- Global Market for Noninvasive Prenatal Testing
- Global Market for Liquid Biopsy in Cancer Applications
- Global Market for Liquid Biopsy for Cancer Diagnostics by Cancer Site
- Global Market for Liquid Biopsy in Cancer Applications by Purpose of Analysis
- Global Market for Liquid Biopsy in Cancer Applications by Biomarker Class
- Global Market for Liquid Biopsy in Cancer Applications by Analysis Method
- Global Market for Liquid Biopsy for Transplant Diagnostics
- Global Market for Liquid Biopsy by Geographic Region
Chapter 10 Patent Review/New Developments
- Patents on Circulating Tumor Cell (CTC) Technologies
- Patents on Exosome Technologies
- Patents on Cell-Free DNA Technologies
- Biomarker-Related Patents
- Patent Considerations for the Use of Artificial Intelligence in Cancer Diagnostics
- Lawsuits on Liquid Biopsy Patents
Chapter 11 Company Profiles
- 4D Lifetec Ag
- Accuragen Inc.
- Accurome Health Inc.
- Adaptive Biotechnologies Inc.
- Advanced Cell Diagnostics Inc.
- Agilent Technologies Inc.
- Akadeum Life Sciences
- Alcediag
- Amoy Diagnostics Co., Ltd.
- Angle Plc
- Apocell Inc.
- Apostle Inc.
- Arcedi Biotech Aps
- Archer Dx
- Arup Laboratories
- Asuragen Inc.
- Aviva Biomed Inc.
- Aviva Biosciences
- Bard1 Life Sciences Ltd.
- Base Genomics
- Baylor Genetics
- Becton, Dickinson And Co.
- Berry Genomics Co., Ltd.
- Bgi Shenzhen
- Biocartis Nv
- Biocept Inc.
- Biodesix Inc.
- Biofluidica Inc.
- Biogazelle
- Biolidics Ltd.
- Biological Dynamics Inc.
- Bioprognos Sl
- Bio-Rad Laboratories Inc.
- Bio-Techne Corp.
- Bitbiome Inc.
- Bluestar Genomics Inc.
- Burning Rock Biotech Ltd.
- C2I Genomics
- Cadex Genomics Corp.
- Cambridge Epigenetix
- Cancer Genetics Inc.
- Canexia Health
- Capio Biosciences
- Captis Diagnostics Inc.
- Caredx Inc.
- Caris Life Science
- Cegat Gmbh
- Cellmax Life
- Cell Microsystems Inc.
- Celsee Diagnostics
- Celtic B.V.
- Chronix Biomedical
- Circulogene Theranostics
- Claret Bioscience
- Clinical Genomics Technologies
- Codiak Biosciences
- Cradle Genomics
- Cyclomics
- Cygnus Biosciences Co., Ltd.
- Cytotrack Aps
- Danaher Corp.
- Datar Cancer Genetics Ltd.
- Delfi Diagnostics
- Diacarta Inc.
- Diagnologix Llc
- Diagnomics
- Diamir Bio
- Dnalytics
- Dnanexus Inc.
- Dovetail Genomics Llc
- Earlydx Inc.
- Edp Biotech Corp.
- Epic Sciences Inc.
- Epigenomics Ag
- Eurofins Scientific
- Exact Sciences Corp.
- Exosome Sciences Inc.
- Exopert
- Exosomics Spa
- Ezlife Bio Inc.
- Fabric Genomics
- Fluxion Biosciences Inc.
- Freenome Inc.
- Genapsys Inc.
- Genecast Inc.
- Genedx Inc.
- Genetron Health Technologies
- Geneseq Biosciences Pty Ltd.
- Genexosome Technologies Inc.
- Genomictree
- Genomoncology
- Genosaber
- Genosity
- Grail Inc.
- Guardant Health Inc.
- Htg Molecular Diagnostics Inc.
- Idl Biotech
- Id Solutions
- Illumina Inc.
- Immunovia Ab
- Incelldx Inc.
- Inex Innovate Pte. Ltd.
- Inivata Ltd.
- Interpace Biosciences Inc.
- Invitae Inc.
- Invivoscribe Inc.
- Jabrehoo Medtech Co., Ltd.
- Jbs Science Inc.
- Koninklijke Philips N.V.
- Laboratory Corp. Of America Inc.
- Labrinth Biotech Inc.
- Lariat Biosciences Inc.
- Lexent Bio Inc.
- Liquid Biopsy Labs
- Lucence Diagnostics Pte. Ltd.
- Lunglife Ai Inc.
- Mdna Life Sciences Inc.
- Mdxhealth Inc.
- Medgenome Inc.
- Menarini Silicon Biosystems Spa
- Merck Kgaa
- Micareo Rare Cell Diagnostics
- Mir Scientific
- Mirxes
- Mursla Ltd
- Mutantdx
- Myriad Genetics Inc.
- Namocell Inc.
- Nanostring Technologies Inc.
- Nanoview Biosciences Inc.
- Natera Inc.
- Naveris Inc.
- Neogenomics Laboratories
- Neo New Oncology Gmbh
- New England Biolabs
- New Horizon Health Ltd.
- Nipd Genetics
- Novigenix Sa
- Novogene Co., Ltd.
- Nrichdx Inc.
- Nucleix
- Nuprobe Inc.
- Nx Prenatal Inc.
- Oncimmune Holdings Plc
- Oncocyte Corp.
- Oncodna S.A.
- Oncolab Diagnostics Gmbh
- Opko Health
- Otraces Inc.
- Oxford Nanopore Technologies Ltd.
- Pacific Biosciences Of California Inc.
- Pangaea Oncology
- Personal Genome Diagnostics Inc.
- Persuasive
- Pfdena Inc.
- Phase Scientific
- Pieriandx
- Predicine Inc.
- Provista Diagnostics Inc.
- Qcdx Llc
- Qiagen Nv
- Quantapore Inc.
- Quantgene Inc.
- Quantum Biosystems Inc.
- Quantumdx
- Quest Diagnostics Inc.
- Rarecells Sas
- Ravgen
- Real Time Genomics Inc.
- Resolution Bioscience Inc.
- Roche Holding Ag
- Saga Diagnostics Ab
- Sanomics Ltd.
- Sano Genetics
- Screencell
- Seekin
- Seer Inc.
- Seracare Life Sciences Inc.
- Sequencing.Com
- Seven Bridges Genomics Inc.
- Single Technologies
- Singlera Genomics Inc.
- Smartcactch
- Somalogic Inc.
- Stage Zero Life Sciences
- Stilla Technologies
- Strand Life Sciences Pvt., Ltd.
- Strata Oncology
- Stratos Genomics Inc.
- Syapse
- Sysmex Inostics Gmbh
- Tailai Biosciences Co., Ltd.
- Takara Bio Inc.
- Telexos Gmbh
- Thermo Fisher Scientific Inc.
- Twinstrand Biosciences
- Tymora Analytical Operations Llc
- Ubiquity Genomics Inc.
- Universal Diagnostics Sl
- Vela Diagnostics
- Veracyte
- Volitionrx
- Vortex Biosciences
- Xing Technologies Llc
- Yikon Genomics Co., Ltd.
- Yourgene Health Plc
List of Tables
Summary Table: Global Market for Liquid Biopsy, by Disease Class, Through 2025
Table 1: Liquid Biopsy Sample Types and Characteristics
Table 2: Scope of Liquid Biopsy Report
Table 3: Global Market for Liquid Biopsy, by Analysis Type, Through 2025
Table 4: Forces Driving Growth in the Market for Liquid Biopsy
Table 5: Key Trends in the Market for Liquid Biopsy
Table 6: Liquid Biopsy Industry Subsectors
Table 7: Liquid Biopsy Biomarker Classes
Table 8: Single-Cell Analysis to Identify Cancer Driver Mutations
Table 9: Genomics-Based Oncology Workflow
Table 10: Unique Challenges of CTC Capture and Analysis
Table 11: CTC Workflow
Table 12: Cell Differentiators
Table 13: Cell Isolation Technologies and Performance
Table 14: CTC Sample Preparation Technologies
Table 15: Single-Cell Analysis Technologies
Table 16: Estimated Annual Solid Biopsy Procedures Performed in the U.S. for Selected Cancers, by Cancer Indication
Table 17: Main Risks of Needle-Based Tissue Biopsies
Table 18: Factors in Tissue Biopsy
Table 19: Prenatal Invasive Testing Technologies
Table 20: Invasive vs. Noninvasive Prenatal Technologies
Table 21: Liquid Biopsy-Related Research and Development Initiatives and Programs
Table 22: Single-Cell Core Research Facilities
Table 23: Population Sequencing Projects
Table 24: Source of Foreign Biomarkers for Liquid Biopsy Applications
Table 25: Precision Medicine Driven by Common Cancer Genetic Mutations
Table 26: Liquid Biopsy Biomarker Types
Table 27: Market Segments of Liquid Biopsy in Cancer Applications
Table 28: NIPT Screening Applications
Table 29: Ethical Issues Associated with NIPT
Table 30: Transplant Diagnostic Applications
Table 31: Key Segments and Trends within the Liquid Biopsy Industry
Table 32: Advanced Sequencing Industry Company Positioning
Table 33: Long-Read Sequencing Industry
Table 34: Sequencing Informatics Industry
Table 35: PCR Companies
Table 36: Advantages of Droplet Digital PCR
Table 37: Digital PCR Liquid Biopsy Industry
Table 38: Main Companies of CTC Separations Industry
Table 39: Liquid Biopsy Assay Industry: Company Focus
Table 40: Examples of NGS-Based Liquid Biopsy Market Differentiation
Table 41: Multi-Cancer Screening Test Desired Features
Table 42: Shed Rates of Various Cancers
Table 43: Cancer Screening Liquid Biopsy Industry
Table 44: Thrive Earlier Detection (Exact Sciences) Cancer Targets
Table 45: Colorectal Cancer Early Detection/Screening Liquid Biopsy Industry
Table 46: Key Clinical Trials for Single- and Multi-Cancer Liquid Biopsy Assays
Table 47: Key Companies in the NIPT Industry
Table 48: Acquisitions in the Liquid Biopsy Industry, January 2019-January 2021
Table 49: Strategic Alliances in the Liquid Biopsy Industry, January 2019-January 2021
Table 50: Key Forces Driving Growth of Liquid Biopsy and Implications
Table 51: Global Market for Liquid Biopsy, by Clinical Category, Through 2025
Table 52: Global Market for Liquid Biopsy, by Purpose of Analysis, Through 2025
Table 53: Global Market for Liquid Biopsy, by Biomarker Type, Through 2025
Table 54: FDA-Approved or CE-Marked Tests with Epigenetic Component
Table 55: Global Market for Liquid Biopsy, by Analysis Platform, Through 2025
Table 56: Global Market for NIPT, by Purpose of Analysis, Through 2025
Table 57: Global Market for NIPT, by Risk Type, Through 2025
Table 58: Global Market for NIPT Diagnostics, by Biomarker Class, Through 2025
Table 59: Global Market for NIPT, by Analysis Method, Through 2025
Table 60: Limitations of Solid Biopsy in Cancer Applications
Table 61: Low-Frequency Mutation Detection
Table 62: Global Market for Liquid Biopsy for Cancer Diagnostics, by Cancer Site, Through 2025
Table 63: Five-Year Survival Rate for Ovarian Cancer
Table 64: National Institutes of Health Liquid Biopsy Early Detection Initiative
Table 65: Lung Cancer Liquid Biopsy Clinical Trials
Table 66: Global Liquid Biopsy Cancer Market, by Purpose of Analysis, Through 2025
Table 67: MRI and Liquid Biopsy Methods
Table 68: Early Detection Tissue of Origin Approaches
Table 69: Global Market for Liquid Biopsy in Cancer Applications, by Biomarker Class, Through 2025
Table 70: Global Market for Liquid Biopsy in Cancer Applications, by Analysis Method, Through 2025
Table 71: Global Market for Liquid Biopsy in Transplant Applications, by Organ Type, Through 2025
Table 72: Transplant Procedures Performed in the U.S., by Organ, 2018-2020
Table 73: Global Market for Liquid Biopsy in Transplant Applications, by Purpose of Analysis, Through 2025
Table 74: Global Market for Liquid Biopsy in Transplant Applications, by Biomarker Class, Through 2025
Table 75: Global Market for Liquid Biopsy in Transplant Applications, by Analysis Method, Through 2025
Table 76: Global Market for Liquid Biopsy, by Region, Through 2025
Table 77: Global Market for Liquid Biopsy in Cancer Applications, by Region, Through 2025
Table 78: Global Market for Liquid Biopsy for NIPT, by Region, Through 2025
Table 79: Global Market for Liquid Biopsy in Transplant Applications, by Region, Through 2025
Table 80: Patent Activity on Circulating Tumor Cell Technologies, by Country/Region, January 2010-June 2020
Table 81: Patent Activity on Exosome Technologies, by Country/Region, January 2010-December 2020
Table 82: Patent Activity on Cell-Free DNA Technologies, by Country/Region, January 2010-December 2020
Table 83: Patent Activity on Cancer Biomarkers, by Country/Region, January 2010-December 2020
Table 84: Status of Liquid Biopsy Patent Disputes
List of Figures
Summary Figure: Global Market for Liquid Biopsy, by Disease Class, 2019-2025
Figure 1: How Cancer Genomics Drives Liquid Biopsy
Executive Summary
Liquid biopsy represents a very attractive option as a supplement or alternative to doing a tissue biopsy for applications in reproductive health, cancer and transplant medicine. A liquid biopsy involves detecting and analyzing “foreign”-derived biomarkers present in body fluids such as blood or urine. The origin of the biomarker defines the liquid biopsy application: tumor (cancer applications); fetus (prenatal screening applications); or transplanted organ (transplant medicine applications).
Liquid biopsy is creating a paradigm shift in medicine, and this is opening significant market opportunities. These market segments are particularly promising for the following liquid biopsy applications: noninvasive prenatal screening for average-risk populations; cancer screening and early detection; and recurrence monitoring for cancer patients.
Biomarker types of most interest include cell-free DNA (cfDNA), circulating tumor cells (CTCs) and exosomes. Ongoing advances in sensitive molecular technologies such as next-generation DNA sequencing (NGS) and digital polymerase chain reaction (dPCR) enable the detection of biomarkers that are present in fluids at very low concentrations, creating entry points for early disease detection and for the monitoring of disease recurrence.
When compared with conventional tissue biopsy, liquid biopsy tests address a significant medical need by delivering a biopsy that is non-invasive and has little or no risk of medical complications. The validation of this testing platform and demonstration of clinical utility has been proven in the high-risk pregnancy segment of the NIPT industry, resulting in high market penetration. This early success is now translating to additional market opportunities in prenatal testing, cancer management, and transplant medicine.
Companies Mentioned
- 4D Lifetec Ag
- Accuragen Inc.
- Accurome Health Inc.
- Adaptive Biotechnologies Inc.
- Advanced Cell Diagnostics Inc.
- Agilent Technologies Inc.
- Akadeum Life Sciences
- Alcediag
- Amoy Diagnostics Co., Ltd.
- Angle Plc
- Apocell Inc.
- Apostle Inc.
- Arcedi Biotech Aps
- Archer Dx
- Arup Laboratories
- Asuragen Inc.
- Aviva Biomed Inc.
- Aviva Biosciences
- Bard1 Life Sciences Ltd.
- Base Genomics
- Baylor Genetics
- Becton, Dickinson And Co.
- Berry Genomics Co., Ltd.
- Bgi Shenzhen
- Bio-Rad Laboratories Inc.
- Bio-Techne Corp.
- Biocartis Nv
- Biocept Inc.
- Biodesix Inc.
- Biofluidica Inc.
- Biogazelle
- Biolidics Ltd.
- Biological Dynamics Inc.
- Bioprognos Sl
- Bitbiome Inc.
- Bluestar Genomics Inc.
- Burning Rock Biotech Ltd.
- C2I Genomics
- Cadex Genomics Corp.
- Cambridge Epigenetix
- Cancer Genetics Inc.
- Canexia Health
- Capio Biosciences
- Captis Diagnostics Inc.
- Caredx Inc.
- Caris Life Science
- Cegat Gmbh
- Cell Microsystems Inc.
- Cellmax Life
- Celsee Diagnostics
- Celtic B.V.
- Chronix Biomedical
- Circulogene Theranostics
- Claret Bioscience
- Clinical Genomics Technologies
- Codiak Biosciences
- Cradle Genomics
- Cyclomics
- Cygnus Biosciences Co., Ltd.
- Cytotrack Aps
- Danaher Corp.
- Datar Cancer Genetics Ltd.
- Delfi Diagnostics
- Diacarta Inc.
- Diagnologix Llc
- Diagnomics
- Diamir Bio
- Dnalytics
- Dnanexus Inc.
- Dovetail Genomics Llc
- Earlydx Inc.
- Edp Biotech Corp.
- Epic Sciences Inc.
- Epigenomics Ag
- Eurofins Scientific
- Exact Sciences Corp.
- Exopert
- Exosome Sciences Inc.
- Exosomics Spa
- Ezlife Bio Inc.
- Fabric Genomics
- Fluxion Biosciences Inc.
- Freenome Inc.
- Genapsys Inc.
- Genecast Inc.
- Genedx Inc.
- Geneseq Biosciences Pty Ltd.
- Genetron Health Technologies
- Genexosome Technologies Inc.
- Genomictree
- Genomoncology
- Genosaber
- Genosity
- Grail Inc.
- Guardant Health Inc.
- Htg Molecular Diagnostics Inc.
- Id Solutions
- Idl Biotech
- Illumina Inc.
- Immunovia Ab
- Incelldx Inc.
- Inex Innovate Pte. Ltd.
- Inivata Ltd.
- Interpace Biosciences Inc.
- Invitae Inc.
- Invivoscribe Inc.
- Jabrehoo Medtech Co., Ltd.
- Jbs Science Inc.
- Koninklijke Philips N.V.
- Laboratory Corp. Of America Inc.
- Labrinth Biotech Inc.
- Lariat Biosciences Inc.
- Lexent Bio Inc.
- Liquid Biopsy Labs
- Lucence Diagnostics Pte. Ltd.
- Lunglife Ai Inc.
- Mdna Life Sciences Inc.
- Mdxhealth Inc.
- Medgenome Inc.
- Menarini Silicon Biosystems Spa
- Merck Kgaa
- Micareo Rare Cell Diagnostics
- Mir Scientific
- Mirxes
- Mursla Ltd
- Mutantdx
- Myriad Genetics Inc.
- Namocell Inc.
- Nanostring Technologies Inc.
- Nanoview Biosciences Inc.
- Natera Inc.
- Naveris Inc.
- Neo New Oncology Gmbh
- Neogenomics Laboratories
- New England Biolabs
- New Horizon Health Ltd.
- Nipd Genetics
- Novigenix Sa
- Novogene Co., Ltd.
- Nrichdx Inc.
- Nucleix
- Nuprobe Inc.
- Nx Prenatal Inc.
- Oncimmune Holdings Plc
- Oncocyte Corp.
- Oncodna S.A.
- Oncolab Diagnostics Gmbh
- Opko Health
- Otraces Inc.
- Oxford Nanopore Technologies Ltd.
- Pacific Biosciences Of California Inc.
- Pangaea Oncology
- Personal Genome Diagnostics Inc.
- Persuasive
- Pfdena Inc.
- Phase Scientific
- Pieriandx
- Predicine Inc.
- Provista Diagnostics Inc.
- Qcdx Llc
- Qiagen Nv
- Quantapore Inc.
- Quantgene Inc.
- Quantum Biosystems Inc.
- Quantumdx
- Quest Diagnostics Inc.
- Rarecells Sas
- Ravgen
- Real Time Genomics Inc.
- Resolution Bioscience Inc.
- Roche Holding Ag
- Saga Diagnostics Ab
- Sano Genetics
- Sanomics Ltd.
- Screencell
- Seekin
- Seer Inc.
- Sequencing.Com
- Seracare Life Sciences Inc.
- Seven Bridges Genomics Inc.
- Single Technologies
- Singlera Genomics Inc.
- Smartcactch
- Somalogic Inc.
- Stage Zero Life Sciences
- Stilla Technologies
- Strand Life Sciences Pvt., Ltd.
- Strata Oncology
- Stratos Genomics Inc.
- Syapse
- Sysmex Inostics Gmbh
- Tailai Biosciences Co., Ltd.
- Takara Bio Inc.
- Telexos Gmbh
- Thermo Fisher Scientific Inc.
- Twinstrand Biosciences
- Tymora Analytical Operations Llc
- Ubiquity Genomics Inc.
- Universal Diagnostics Sl
- Vela Diagnostics
- Veracyte
- Volitionrx
- Vortex Biosciences
- Xing Technologies Llc
- Yikon Genomics Co., Ltd.
- Yourgene Health Plc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 345 |
| Published | March 2021 |
| Forecast Period | 2020 - 2025 |
| Estimated Market Value ( USD | $ 3.8 Billion |
| Forecasted Market Value ( USD | $ 19.6 Billion |
| Compound Annual Growth Rate | 38.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 206 |
